VANGUARD GROUP INC 13D and 13G filings for CytomX Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-26 5:40 pm Sale | 2026-03-13 | 13G | CYTOMX THERAPEUTICS INC CTMX | VANGUARD GROUP INC | 0 0.000% | -9,379,794 (Position Closed) | Filing |
| 2025-07-29 11:22 am Purchase | 2025-06-30 | 13G | CYTOMX THERAPEUTICS INC CTMX | VANGUARD GROUP INC | 9,379,794 5.950% | 4,476,851 (+91.31%) | Filing |
| 2024-02-13 5:02 pm Purchase | 2023-12-29 | 13G | CYTOMX THERAPEUTICS INC CTMX | VANGUARD GROUP INC | 4,902,943 7.320% | 317,222 (+6.92%) | Filing |
| 2023-02-09 11:16 am Sale | 2022-12-30 | 13G | CYTOMX THERAPEUTICS INC CTMX | VANGUARD GROUP INC | 4,585,721 6.940% | -522,270 (-10.22%) | Filing |
| 2022-02-09 3:43 pm Purchase | 2021-12-31 | 13G | CYTOMX THERAPEUTICS INC CTMX | VANGUARD GROUP INC | 5,107,991 7.830% | 2,173,567 (+74.07%) | Filing |